Navigation Links
2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
Date:12/13/2007

CLEVELAND, Ohio, December 13 /PRNewswire/ -- Ten new validation studies were published during 2007 on the Simbionix Mentor series of training simulators, bringing the total number of studies published to 65.

"This year we have seen a considerable increase in interest from US and European institutes" said Gary Zamler, Simbionix' CEO. "Some of the world's most highly respected academic medical institutions and teaching hospitals have completed studies measuring the efficacy of using Simbionix Mentor simulation products."

The studies published this year include two new studies on the GI Mentor, two on the URO/PERC platform, three on the LAP Mentor and three on the ANGIO Mentor. Some of the studies were carried out at multiple sites, something that typically increases the reliability of study results. The institutes which conducted studies include the University of Texas, Catharina Hospital of the Netherlands, the British Imperial College of London and the Graduate School of Medical Sciences in the Kyushu University of Fukuoka, the first study by a Japanese institute to date.

The study carried out by experts at Catharina Hospital's Department of Gastroenterology concluded that the GI Mentor II simulator offered a convincing, realistic representation of colonoscopy that can discriminate between different levels of colonoscopy expertise. As a result, the product was granted both construct validity and expert validity. The study carried out by Kyushu University of Fukuoka concluded that the LAP Mentor was able to differentiate between subjects with different laparoscopic experience.

One of the key value points for medical institutions to use Simbionix products is the ability to offer clinicians and medical students the required hands-on surgical experience at zero patient risk. Validation studies are critical to prove the efficacy of the simulation experience, so that institutions can rely on simulators to advance clinician training and improve patient safety. Yael Friedman Ph.D., Simbionix Chief Scientist over Medical Projects noted "We are happy to see that all of the institutes which have validated our products continue to demonstrate the effectiveness and advantage of using our Mentor products for surgical training".

Full details of the validation tests carried out can be seen on Simbionix website:

- For LAP Mentor validation tests, see http://www.simbionix.com/Media_validation_LAP.html

- For ANGIO Mentor validation tests, see http://www.simbionix.com/Media_validation_ANGIO.html

- For GI Mentor validation tests, see http://www.simbionix.com/Media_validation.html

- For URO Mentor validation tests, see http://www.simbionix.com/Media_validation_URO.html

About Simbionix USA Corporation

Simbionix is the industry leader in the development of innovative and effective medical simulation products used for clinical education and training of medical professionals. Simbionix products are designed to accelerate best-practice medical training, advance clinical performance and improve patient safety. The company is committed to continuously innovating and broadening its product offerings with a wide range of training modules, case studies and scenarios, developed in response to the growing importance of clinical training and education as a means of achieving improved patient care.
Additional company information can be found at http://www.simbionix.com

Contact:

Inbal Mazor,

VP Marketing,

mailto:inbal@simbionix.com,

+1-216-229-2040


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
2. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
3. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
4. Life on Mars pregnancy test successfully launched
5. Of mice and men: new male contraceptives successful in rodents and humans
6. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
9. James Webb Space Telescope marks successful completion
10. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalinkā„¢ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):